2026年6月25日 · 自动抓取 · 最新研究 · 1 分钟阅读

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD

Bone Marrow Transplantation, Published online: 25 June 2026; doi:10.1038/s41409-026-02942-wIntegrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD

本文自动抓取自 Bone Marrow Transplantation，原文链接：Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD

原文发布日期：2026-06-25

Back to Blog

View All Posts »

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

Blood Cancer Journal, Published online: 24 June 2026; doi:10.1038/s41408-026-01549-0Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

The overall survival of children with newly diagnosed acute myeloid leukemia (AML) in high-income countries has increased to 80% over the past decades. Nevertheless, a significant subset of patients e

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

Leukemia, Published online: 18 June 2026; doi:10.1038/s41375-026-03001-5Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients:

Detection of <i>MEN1</i> resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors

Blood Cancer Journal, Published online: 16 June 2026; doi:10.1038/s41408-026-01545-4Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors

Related Posts

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

Detection of <i>MEN1</i> resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors